Enforced effect of tk-MCP-1 fusion gene in ovarian cancer

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Hong, Shuhui ^a,b   Zhang, Ping ^a,c   Zhang, Hui ^a   Jia, Lin ^a   Qu, Xun ^a   Yang, Qifeng ^a   Rong, Fengnian ^b   Kong, Beihua ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Gene therapy; Herpes simplex virus thymidine kinase; Monocyte chemoattractant protein 1; Ovarian neoplasma; SCID

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; RETROVIRUS VECTOR; TK MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG MECHANISM; FEMALE; FUSION GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; MONOCYTE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RIBOSOME; SUICIDE GENE THERAPY; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOKINE CCL2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, SCID; ONCOGENE PROTEINS, FUSION; OVARIAN NEOPLASMS; THYMIDINE KINASE;

EID: 84866045373     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-74     Document Type: Article

References (32)

1. Symptom interpretation and health care seeking in ovarian cancer. Seibaek L, Petersen LK, Blaakaer J, Hounsgaard L, BMC Womens Health 2011 11 31 10.1186/1472-6874-11-31 21699682
2. ESRRA-C11orf20 Is a Recurrent Gene Fusion in Serous Ovarian Carcinoma. Salzman J, Marinelli RJ, Wang PL, Green AE, Nielsen JS, Nelson BH, et al. PLoS Biol 2011 9 1001156 10.1371/journal.pbio.1001156 21949640
3. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Agarwal R, Kaye SB, Nat Rev Cancer 2003 3 502 516 10.1038/nrc1123 12835670 (Pubitemid 37328838)
4. Virus-directed enzyme/prodrug therapy (VDEPT). Selectively engineering drug sensitivity into tumors. Huber BE, Richards CA, Austin EA, Ann N Y Acad Sci 1994 716 104 14 discussion 40-43 10.1111/j.1749-6632.1994.tb21706.x 8024189 (Pubitemid 24228104)
5. Gene-directed enzyme prodrug therapy with a mustard prodrug/ carboxypeptidase G2 combination. Marais R, Spooner RA, Light Y, Martin J, Springer CJ, Cancer Res 1996 56 4735 4742 8840992 (Pubitemid 26338078)
6. Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study. Lv SQ, Zhang KB, Zhang EE, Gao FY, Yin CL, Huang CJ, et al. Med Sci Monit 2009 15 R13 BR20 19114960
7. Cytokine-enhanced vaccine and suicide gene therapy as adjuvant treatments of metastatic melanoma in a horse. Finocchiaro LM, Riveros MD, Glikin GC, Vet Rec 2009 164 278 279 10.1136/vr.164.9.278 19252217
8. Effects of recombinant adenovirus-mediated double suicide genes on implanted human keloid: experiment with athymic mice. Xu B, Liu ZZ, Zhang J, Zong XL, Cai JL, Zhonghua yi xue za zhi 2008 88 3428 3431 19159576
9. Gap junctions play a role in the bystander effect of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, et al. Gene Ther 1996 3 85 92 8929915 (Pubitemid 26088496)
10. A distant bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Kianmanesh AR, Perrin H, Panis Y, Fabre M, Nagy HJ, Houssin D, et al. Hum Gene Ther 1997 8 1807 1814 10.1089/hum.1997.8.15-1807 9358030 (Pubitemid 27488930)
11. Human monocyte chemoattractant protein-1: structure and function. Yoshimura T, Leonard EJ, Cytokines 1992 4 131 152 1472914
12. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA, Proc Natl Acad Sci U S A 1994 91 3652 3656 10.1073/pnas.91.9.3652 8170963 (Pubitemid 24139489)
13. Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation. Tsuchiyama T, Nakamoto Y, Sakai Y, Mukaida N, Kaneko S, Cancer Sci 2008 99 2075 2082 10.1111/j.1349-7006.2008.00951.x 19016769
14. Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1- and 5-dependent manner in mice. Iida N, Nakamoto Y, Baba T, Kakinoki K, Li YY, Wu Y, et al. J Leukoc Biol 2008 84 1001 1010 10.1189/jlb.1107791 18644849
15. Combinatory gene therapy with electrotransfer of midkine promoter-HSV-TK and interleukin-21. Hanari N, Matsubara H, Hoshino I, Akutsu Y, Nishimori T, Murakami K, et al. Anticancer Res 2007 27 2305 2310 17695518 (Pubitemid 47228068)
16. Pedroso de Lima MC. Evaluation of the antitumoral effect mediated by IL-12 and HSV-tk genes when delivered by a novel lipid-based system. Faneca H, Cabrita AS, Simoes S, Biochim Biophys Acta 2007 1768 1093 1102 10.1016/j.bbamem.2006.12.017 17296164 (Pubitemid 46550345)
17. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Majumdar AS, Zolotorev A, Samuel S, Tran K, Vertin B, Hall-Meier M, et al. Cancer Gene Ther 2000 7 1086 1099 10.1038/sj.cgt.7700215 10917212 (Pubitemid 30483489)
18. Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Barton KN, Stricker H, Elshaikh MA, Pegg J, Cheng J, Zhang Y, et al. Mol Ther J Am Soc Gene Ther 2011 19 1353 1359 10.1038/mt.2011.89
19. Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Tsuchiyama T, Kaneko S, Nakamoto Y, Sakai Y, Honda M, Mukaida N, et al. Cancer Gene Ther 2003 10 260 269 10.1038/sj.cgt.7700571 12679798 (Pubitemid 36423107)
20. Retroviral vectors: post entry events and genomic alterations. Nowrouzi A, Glimm H, von Kalle C, Schmidt M, Viruses 2011 3 429 455 10.3390/v3050429 21994741
21. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer. Zhang Z, Huang Y, Newman K, Gu J, Zhang X, Wu H, et al. Clin Cancer Res 2009 15 5154 5160 10.1158/1078-0432.CCR-09-0025 19671855
22. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. Jiang Y, Beller DI, Frendl G, Graves DT, J Immunol 1992 148 2423 2428 1348518
23. Structure and function of the leukocyte adhesion molecules CD11/CD18. Arnaout MA, Blood 1990 75 1037 1050 1968349 (Pubitemid 20086807)
24. Macrophage therapy of cancer metastasis. Fidler IJ, CIBA Found Symp 1988 141 211 222 3075934
25. Tumor-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors. Yamashiro S, Takeya M, Nishi T, Kuratsu J, Yoshimura T, Ushio Y, et al. Am J Pathol 1994 145 856 867 7943176 (Pubitemid 24320603)
26. Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy. Ramesh R, Munshi A, Marrogi AJ, Freeman SM, Int J Cancer 1999 80 380 6 10.1002/(SICI)1097-0215(19990129)80:3<380::AID- IJC8>3.0.CO;2-G 9935178 (Pubitemid 29019624)
27. The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells. Freeman SM, Ramesh R, Shastri M, Munshi A, Jensen AK, Marrogi AJ, Cancer Lett 1995 92 167 174 10.1016/0304-3835(95)03771-N 7600527
28. Prodrug-activated gene therapy: involvement of an immunological component in the bystander effect Gagandeep S, Brew R, Green B, Christmas SE, Klatzmann D, Poston GJ, et al. Cancer Gene Ther 1996 3 83 88 8729906 (Pubitemid 126732427)
29. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Chen SH, Kosai K, Xu B, Pham-Nguyen K, Contant C, Finegold MJ, et al. Cancer Res 1996 56 3758 3762 8706021 (Pubitemid 26272026)
30. Clinical significance of combined immunohistochemical detection of CD44v and sialyl LeX expression for colorectal cancer patients undergoing curative resection. Yamaguchi A, Goi T, Seki K, Ohtaki N, Maehara M, Kobayashi T, et al. Oncology 1998 55 400 403 10.1159/000011885 9732216
31. Expression of CD44 variants and its association with survival in pancreatic cancer. Gotoda T, Matsumura Y, Kondo H, Saitoh D, Shimada Y, Kosuge T, et al. Jpn J Cancer Res 1998 89 1033 1040 10.1111/j.1349-7006.1998.tb00493.x 9849582 (Pubitemid 28544779)
32. Immune system in suicide-gene therapy. Freeman SM, Ramesh R, Marrogi AJ, Lancet 1997 349 2 3 10.1016/S0140-6736(97)22001-5 8988108 (Pubitemid 27022977)